Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Envista HoldingsMEX:NVST 80 ROE % is 5.01% as of Mar. 2026, which is 7% above its 10-year median of 4.70. GuruFocus rates MEX:NVST with a GF Score™ of 80/100 and a GF Value™ of MXN332.83. The stock has 4 warning signs investors should review. Among 798 Medical Devices & Instruments companies, Envista Holdings ranks worse than 51.38% on this metric.
The historical rank and industry rank for Envista Holdings's ROE % or its related term are showing as below:
MEX:NVST'
s ROE % Range Over the Past 10 Years
Min: -31.47 Med: 4.7 Max: 8.76
Current: 2.19
During the past 10 years, Envista Holdings's highest ROE % was 8.76%. The lowest was -31.47%. And the median was 4.70%.
MEX:NVST's ROE % is ranked worse than 51.38% of 798
companies
in the Medical Devices & Instruments industry
Industry Median: 2.51
vs MEX:NVST: 2.19
Envista Holdings (MEX:NVST) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Envista Holdings ROE % Related Terms
Envista Holdings ROE % Historical Data
* Premium members only.
The historical data trend for Envista Holdings's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Envista Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Envista Holdings ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Envista Holdings's ROE % distribution charts can be found below:
* The bar in red indicates where Envista Holdings's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Envista Holdings (MEX:NVST) has a ROE % of 5.01% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Envista Holdings and its competitors. This is near median its historical median of 4.70. According to the industry distribution chart, Envista Holdings ranks #410 out of 798 companies in the Medical Devices & Instruments industry, placing it in the top 51.4%.
Is Envista Holdings' ROE % too high?
Envista Holdings' current ROE % of 5.01% is near median its 10-year median of 4.70. The Medical Devices & Instruments industry median ROE % is 2.51. Envista Holdings' value of 5.01% is 99.6% above this industry median. Based on the distribution chart, Envista Holdings ranks #410 out of 798 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Envista Holdings has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Envista Holdings' ROE % compare to MMSI and MMED?
According to the Medical Devices & Instruments industry distribution chart, Envista Holdings ranks #410 out of 798 companies for ROE %. This places Envista Holdings in the lower half of its industry. The industry median ROE % is 2.51. Envista Holdings' value of 5.01% is 99.6% above this benchmark. While the company's 10-year median is 4.70 vs. the industry median of 2.51, Envista Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.51, based on 798 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Envista Holdings's current ROE % of 5.01% is 99.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Envista Holdings and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Envista Holdings's current ROE % is 5.01%, which is near median its own 10-year median of 4.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envista Holdings stock overvalued right now?
Envista Holdings (MEX:NVST) has a current ROE % of 5.01%. The stock's GF Value™ is MXN332.83, compared to a current price of MXN370.00 — trading 11.2% above its estimated fair value. The current ROE % is 5.01%, which is near median its 10-year median of 4.70 and 99.6% above the Medical Devices & Instruments industry median of 2.51. Envista Holdings' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Envista Holdings (MEX:NVST), the current ROE % is 5.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Envista Holdings (MEX:NVST) Overvalued in 2026?
Based on GuruFocus' analysis, Envista Holdings stock appears to be overvalued.
The current stock price of MXN370.00 is trading 11.2% above its estimated GF Value™ of MXN332.83.
Key valuation signals for MEX:NVST:
ROE %: 5.01% (near median its 10-year median of 4.70)
GF Value™: MXN332.83 vs. price of MXN370.00 (11.2% above fair value)
Industry Position: 99.6% above the Medical Devices & Instruments median (#410 of 798)
No single metric tells the full story. See the MEX:NVST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
80GF Score
Get the complete analysis for MEX:NVST
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NVST has been successfully added to your 
